Diagnostic Test Accuracy Protocol

Calcitonin testing for detection of medullary thyroid cancer in patients with thyroid nodules

  1. Hans HG Verbeek1,
  2. Jan Willem B de Groot2,
  3. Wim J Sluiter3,
  4. Anneke C Muller Kobold4,
  5. John TM Plukker5,
  6. Thera P Links1,*

Editorial Group: Cochrane Metabolic and Endocrine Disorders Group

Published Online: 17 OCT 2012

Assessed as up-to-date: 20 AUG 2012

DOI: 10.1002/14651858.CD010159


How to Cite

Verbeek HHG, de Groot JWB, Sluiter WJ, Muller Kobold AC, Plukker JTM, Links TP. Calcitonin testing for detection of medullary thyroid cancer in patients with thyroid nodules (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD010159. DOI: 10.1002/14651858.CD010159.

Author Information

  1. 1

    University of Groningen, Department of Endocrinology, Groningen, Netherlands

  2. 2

    University Medical Center, University of Groningen, Medical Oncology, Groningen, Netherlands

  3. 3

    University Medical Center Groningen, Department of Internal Medicine, Groningen, Netherlands

  4. 4

    University Medical Center, University of Groningen, Laboratory Medicine, Groningen, Netherlands

  5. 5

    University Medical Center, University of Groningen, Onocological Surgery, Groningen, Netherlands

*Thera P Links, Department of Endocrinology, University of Groningen, University Medical Center, Hanzeplein 1, Groningen, 9713 GZ, Netherlands. t.p.links@int.azg.nl.

Publication History

  1. Publication Status: New
  2. Published Online: 17 OCT 2012

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objective of this review is to determine the diagnostic accuracy of calcitonin testing in the detection of MTC in patients with thyroid nodules.

We will investigate whether calcitonin screening should be performed in all patients with thyroid nodules or whether screening should be limited to subgroups of patients. Firstly we will test differences in cut-off values, assay types and different verification methods as these are likely to have the most influence on heterogeneity. Depending on the number of included studies, we will perform further subgroup analyses.

  • Age.
  • Gender.
  • Nodules detected by palpation or ultrasound.
  • Nodule size.
  • Number of nodules.
  • Sonographic morphology of thyroid nodules.
  • FNA procedures performed through ultrasound guidance versus palpation.
  • Basal versus stimulated calcitonin testing.